Moreover, unsuccessful efforts directed toward modifying Aβ production as a treatment for AD (Castello et al, 2014) have raised the possibility that other aspects of APP cleavage may be contributing to these metabolic changes. This evidence concerns the gene APP and Alzheimer disease.